+

WO2019008595A1 - Process for the preparation of 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1- methylpiperidin-4-yl)urea and salts thereof - Google Patents

Process for the preparation of 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1- methylpiperidin-4-yl)urea and salts thereof Download PDF

Info

Publication number
WO2019008595A1
WO2019008595A1 PCT/IN2018/050053 IN2018050053W WO2019008595A1 WO 2019008595 A1 WO2019008595 A1 WO 2019008595A1 IN 2018050053 W IN2018050053 W IN 2018050053W WO 2019008595 A1 WO2019008595 A1 WO 2019008595A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compound
pimavanserin
preparation
group
Prior art date
Application number
PCT/IN2018/050053
Other languages
French (fr)
Inventor
Shailendra Kumar Dubey
Vaibhav MISHRA
Jai Prakash VERMA
Rajendra Singh SHEKHAWAT
Sujay Biswas
Dharam Vir
Original Assignee
Jubilant Generics Limited (Formerly A Division Of Jubilant Life Sciences Limited)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jubilant Generics Limited (Formerly A Division Of Jubilant Life Sciences Limited) filed Critical Jubilant Generics Limited (Formerly A Division Of Jubilant Life Sciences Limited)
Publication of WO2019008595A1 publication Critical patent/WO2019008595A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4

Definitions

  • the present invention relates to an efficient process for the preparation of l-(4- fluorobenzyl)-3-(4-isobutoxybenzyl)-l-(l-methylpiperidin-4-yl)urea and pharmaceutically acceptable salts thereof involving use of novel intermediates.
  • pimavanserin tartrate salt by Acadia Pharmaceuticals which has been approved for use in patients for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.
  • Pimavanserin tartrate is represented structurally as Formula I,
  • Pimavanserin synthesis is disclosed in US 7,601,740 and US 7,790,899, wherein the process involves the reaction of N-(4-fluorobenzyl)-l-methylpiperidine-4-amine with 1- isobutoxybenzyl isocyanate.
  • the patents disclose the preparation of intermediate 1- isobutoxybenzyl isocyanate via two processes wherein one process involves reaction of 2- (4-isobutoxyphenyl)acetic acid with diphenyl phosphoryl azide and the other process involves reaction of 4-isobutoxybenzylamine with phosgene or its equivalents.
  • WO2017015272 discloses a process for the preparation of pimavanserin via preparation of variously substituted carbamate intermediates, which are further condensed with another intermediate to obtain pimavanserin.
  • the process using dimethyl carbonate for the preparation of carbamate is carried out in the presence of zirconium catalyst for about 72 hours at high temperature with a proximal yield of 20%.
  • the process involving use of diphenyl carbonate for the preparation of carbamate takes place in about 24 hours.
  • the preparation of carbmate using methyl chloroformate involved column chromatography for the purification of carbamate intermediate to achieve required purity standards.
  • the pimavanserin was obtained by trituration with only 70.5% purity, wherein the carbamte intermediate was prepared using bis(2,2,2-trifluroethyl)carbonate of 2,2,2-trifluoroethyl chloroformate.
  • the processes disclosed involve major challenges to be easily applicable on industrial scale such as use of an expensive catalyst, long reaction time increases energy consumption, which increases overall production cost.
  • the process providing pimavanserin with purity of 70% will attract additional purifications, thereby leading to loss of yield and increase in cost.
  • the procedure of trituration is not at all advisable at industrial scale.
  • the disclosed processes suffer a number of disadvantages to be successfully implemented on industrial scale.
  • there remains an urgent need for the development of a process which not only overcome one or more problems of the prior art processes as mentioned above, but also is an efficient, safe and convenient process for the preparation of pimavanserin and pharmaceutically acceptable salts thereof.
  • the principal object of present invention relates to novel, efficient and safe processes for the preparation of l-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-l-(l-methylpiperidin-4- yl)urea and pharmaceutically acceptable salts thereof in high yield and purity involving novel intermediates, which alleviates one or more drawbacks of prior art processes.
  • the present invention relates to the compound of formula IV
  • the present invention provides a process for the preparation of compound of formula IV
  • the present invention provides use of compound of formula IV for the preparation of pimavanserin and pharmaceutically acceptable salts thereof, comprising the reaction of formula II or its salt with the compound of formula III to give a compound of formula IV.
  • the next step involves reaction of compound of formula IV with compound of formula V to give pimavanserin of formula IA, according to Scheme 1, which is optionally converted to its pharmaceutically acceptable salts.
  • the present invention relates to the compound of formula VI
  • the present invention provides a process for the preparation of compound of formula VI
  • the present invention provides use of compound of formula VI for the preparation of pimavanserin and pharmaceutically acceptable salts thereof, comprising the reaction of compound of formula V with compound of formula III to give a compound of formula VI.
  • the next step involves reaction of compound of formula VI with compound of formula II or its salt to give pimavanserin of formula IA, according to Scheme 2, which is optionally converted to its pharmaceutically acceptable salts.
  • the present invention provides processes that are simple, convenient, environment friendly and economical for industrial application.
  • the method utilizes use of safer reagents, conditions and novel intermediates that avoids formation of multiple impurities and thereby reduces the additional requirements of purifying intermediates at various stages and accordingly reduces the use of solvents and reagents, which results in decrease in costs attributed to a more efficient use of reagents and solvents and at the same time makes process more environment friendly.
  • the present invention relates to the compound of formula IV:
  • the present invention provides a process for the preparation of compound of formula IV:
  • the compound of formula II or its salt is reacted with compound of formula III to give compound of formula IV.
  • a salt of compound of formula II is used it is selected from the group comprising of hydrochloride, hydrobromide, acetate and the like.
  • the salt is neutralized to compound of formula II by use of base in a solvent, wherein the base used is selected from the group comprising organic and inorganic.
  • the organic base used is selected from the group comprising of trimethylamine and the like.
  • the inorganic base used is selected from alkali and alkaline earth metal carbonates, bicarbonates and the like.
  • the alkali and alkaline earth metal is selected from the group comprising of sodium, potassium, calcium, barium and the like.
  • the solvent used in the liberation of free base of compound of Formula II and further reaction with compound of Formula III can be same or different and is selected from the group comprising of halogenated hydrocarbons such as dichloromethane, chlorobenzene and the like, hydrocarbons such as cyclohexane, heptane, octane, toluene, xylene and the like, esters such as ethyl acetate, propyl acetate and the like, nitrile such as acetonitrile, propionitrile and the like, DMSO, DMF, water and mixtures thereof.
  • halogenated hydrocarbons such as dichloromethane, chlorobenzene and the like
  • hydrocarbons such as cyclohexane, heptane, octane, toluene, xylene and the like
  • esters such as ethyl acetate, propyl acetate and the like
  • nitrile
  • the present invention provides a process for the preparation of pimavanserin involving use of compound of formula IV, comprising the reaction of formula II or its salt with the compound of formula III to give a compound of formula IV.
  • the next step involves reaction of compound of formula IV with compound of formula V to give pimavanserin of formula IA, according to Scheme 1, which is optionally converted to its pharmaceutically acceptable salts.
  • compound of formula II or its salt reacts with compound of formula III to give compound of formula IV.
  • a salt of compound of formula II is used it is selected from the group comprising of hydrochloride, hydrobromide, acetate and the like.
  • the salt is neutralized to compound of formula II by use of base in a solvent, wherein the base used is selected from the group comprising organic and inorganic.
  • the organic base used is selected from the group comprising of trimethylamine and the like.
  • the inorganic base used is selected from alkali and alkaline earth metal carbonates, bicarbonates and the like.
  • the alkali and alkaline earth metal is selected from the group comprising of sodium, potassium, calcium, barium and the like.
  • the solvent used in the liberation of free base of compound of Formula II and further reaction with compound of Formula III can be same or different and is selected from the group comprising of halogenated hydrocarbons such as dichloromethane, chlorobenzene and the like, hydrocarbons such as cyclohexane, heptane, octane, toluene, xylene and the like, esters such as ethyl acetate, propyl acetate and the like, nitrile such as acetonitrile, propionitrile and the like, DMSO, DMF, water and mixtures thereof.
  • halogenated hydrocarbons such as dichloromethane, chlorobenzene and the like
  • hydrocarbons such as cyclohexane, heptane, octane, toluene, xylene and the like
  • esters such as ethyl acetate, propyl acetate and the like
  • nitrile
  • the compound of formula II is optionally isolated after neutralization and is further reacted with compound of formula III to obtain compound of formula IV, which is isolated or is used in-situ for further reaction.
  • the compound of formula IV is treated with compound of formula V, wherein the reaction is carried out in solvent in presence of base.
  • the solvent used is selected from the group comprising of halogenated hydrocarbons such as dichloromethane and the like, esters such as ethyl acetate, isopropyl acetate and the like, nitrile such as acetonitrile, propionitrile and the like, aromatic hydrocarbons such as toluene, chlorobenzene and the like, DMSO, DMF, water and mixtures thereof.
  • the base used is selected from organic and inorganic, wherein organic base used is selected from the group comprising of triethylamine and the like.
  • the inorganic base used is selected from alkali and alkaline earth metal carbonates, bicarbonates and the like.
  • the alkali and alkaline earth metal is selected from the group comprising of sodium, potassium, calcium, barium and the like.
  • the reaction give pimavanserin of formula IA, which is optionally converted to its pharmaceutically acceptable salts.
  • the present invention relates to the compound of formula VI
  • the present invention provides a process for the preparation of compound of formula VI
  • the compound of formula V reacts with compound of formula III in solvent to obtain compound of formula VI.
  • the solvent used is selected from the group comprising of halogenated hydrocarbons such as dichloromethane and the like, esters such as ethyl acetate and the like, nitrile such as acetonitrile, propionitrile and the like, water and mixtures thereof.
  • the present invention provides use of compound of formula VI for the preparation of pimavanserin and pharmaceutically acceptable salts thereof, comprising the reaction of compound of formula V with compound of formula III to give a compound of formula VI.
  • the next step involves reaction of compound of formula VI with compound of formula II or its salt to give pimavanserin of formula IA, according to Scheme 2, which is optionally converted to its pharmaceutically acceptable salts.
  • the N-(4-fluorobenzyl)-l-methylpiperidine-4-amine of formula V reacts with compound of formula III.
  • the reaction is carried out in solvent optionally in presence of base.
  • the solvent used is selected from the group comprising of halogenated hydrocarbons such as dichloromethane and the like, esters such as ethyl acetate and the like, nitrile such as acetonitrile and the like, water and mixtures thereof.
  • the base used is selected from organic and inorganic, wherein organic base used is selected from the group comprising of trimethylamine and the like.
  • the inorganic base used is selected from alkali and alkaline earth metal carbonates, bicarbonates and the like.
  • the alkali and alkaline earth metal is selected from the group comprising of sodium, potassium, calcium, barium and the like.
  • the reaction give compound of formula VI which is optionally isolated and is further used in next step.
  • the compound of formula VI is then treated with 4- isobutoxybenzylamine or its salt of formula II, wherein the 4-isobutoxybenzylamine salt used is selected from the group comprising of hydrochloride, hydrobromide, acetate and the like.
  • the salt is neutralized to compound of formula II by use of base in a solvent, wherein the base used is selected from the group comprising organic and inorganic.
  • the organic base used is selected from the group comprising of trimethylamine and the like.
  • the inorganic base used is selected from alkali and alkaline earth metal carbonates, bicarbonates and the like.
  • the alkali and alkaline earth metal is selected from the group comprising of sodium, potassium, calcium, barium and the like.
  • the reaction is carried out in solvent selected from the group comprising of halogenated hydrocarbons such as dichloromethane and the like, esters such as ethyl acetate and the like, nitrile such as acetonitrile and the like, water and mixtures thereof.
  • the reaction of compound of formula VI with compound of formula II is carried out in presence of solvent, optionally in the presence of a catalyst such as dimethylaminopyridine and the like.
  • the solvent used is selected from the group comprising of esters such as ethyl acetate, isopropyl acetate and the like, aromatic hydrocarbons such as toluene, chlorobenzene and the like, DMSO, DMF, water and mixtures thereof.
  • the pimavanserin of formula IA so obtained is optionally converted to pharmaceutically acceptable salts.
  • the pharmaceutically acceptable salt of pimavanserin is selected from the group comprising of hydrochloride, hydrobromide, tartrate, oxalate and the like.
  • the compound of formula IV, VI and pimavanserin or its pharmaceutically acceptable salt are isolated using one or more work-up processes such as extraction, washing, filtration and the like.
  • the pimavanserin or its pharmaceutically acceptable salt obtained is then optionally crystallized from suitable organic solvent to get pure pimavanserin.
  • the suitable organic solvent for crystallization is selected from the group comprising of alcohols, esters, ketones, ethers, water or mixtures thereof; particularly methanol, ethanol, n-propanol, isopropanol, n-butanol, iso-butanol, tert- butanol, methyl acetate, ethyl acetate, isopropyl acetate, tertiary butyl acetate, acetone, methyl ethyl ketone, di-isopropyl ether, tetrahydrofuran, water or mixtures thereof.
  • pimavanserin or its pharmaceutically acceptable salts obtained is having purity not less than 99.5%, preferably not less than 99.8%.
  • pimavanserin tartrate To solution of pimavanserin (1.5 g) in ethanol (18 ml) slowly added a solution of L- (+)-tartaric acid (0.263 g) in ethanol (12 ml) at 60-65 °C. The resulting clear mixture is slowly cooled to room temperature. The solid so obtained is filtered and dried to obtain pimavanserin tartrate.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

The present invention relates to an efficient process for the preparation of 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1- methylpiperidin-4-yl)urea and pharmaceutically acceptable salts thereof involving use of novel intermediates.

Description

PROCESS FOR THE PREPARATION OF l-(4-FLUOROBENZYL)-3-(4- ISOBUTOXYBENZYL)-l-(l- METHYLPIPERIDIN-4-YL)UREA AND SALTS
THEREOF
Field of the Invention
The present invention relates to an efficient process for the preparation of l-(4- fluorobenzyl)-3-(4-isobutoxybenzyl)-l-(l-methylpiperidin-4-yl)urea and pharmaceutically acceptable salts thereof involving use of novel intermediates.
Background of the Invention l-(4-Fluorobenzyl)-3-(4-isobutoxybenzyl)-l-(l-methylpiperidin-4-yl)urea is known as pimavanserin and has been developed as pimavanserin tartrate salt by Acadia Pharmaceuticals which has been approved for use in patients for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. Pimavanserin tartrate is represented structurally as Formula I,
Figure imgf000002_0001
I
Pimavanserin synthesis is disclosed in US 7,601,740 and US 7,790,899, wherein the process involves the reaction of N-(4-fluorobenzyl)-l-methylpiperidine-4-amine with 1- isobutoxybenzyl isocyanate. The patents disclose the preparation of intermediate 1- isobutoxybenzyl isocyanate via two processes wherein one process involves reaction of 2- (4-isobutoxyphenyl)acetic acid with diphenyl phosphoryl azide and the other process involves reaction of 4-isobutoxybenzylamine with phosgene or its equivalents. The methods mentioned in the patents suffer a number of disadvantages, the main disadvantage involves use of 4-isobutoxybenzyl isocyanate, as isocyanates are known toxic and are highly reactive compounds and thus are very unsafe to handle at industrial scale. Another disadvantage pertains to use of highly toxic reagents such as phosgene and diphenyl phosphoryl azide, which are again toxic and explosive in nature, thereby are highly unsafe to be used at industrial level. The process disclosed not only suffers working incapability but the product obtained i.e. pimavanserin is also not of very high purity as per the required standards and need undue multiple purifications, which leads to loss of yield and thus makes processes highly incapable for industrial application.
WO2017015272 discloses a process for the preparation of pimavanserin via preparation of variously substituted carbamate intermediates, which are further condensed with another intermediate to obtain pimavanserin. Of the various processes disclosed, the process using dimethyl carbonate for the preparation of carbamate is carried out in the presence of zirconium catalyst for about 72 hours at high temperature with a proximal yield of 20%. The process involving use of diphenyl carbonate for the preparation of carbamate takes place in about 24 hours. In another process, the preparation of carbmate using methyl chloroformate involved column chromatography for the purification of carbamate intermediate to achieve required purity standards. In yet another disclosure, the pimavanserin was obtained by trituration with only 70.5% purity, wherein the carbamte intermediate was prepared using bis(2,2,2-trifluroethyl)carbonate of 2,2,2-trifluoroethyl chloroformate. Thus, the processes disclosed involve major challenges to be easily applicable on industrial scale such as use of an expensive catalyst, long reaction time increases energy consumption, which increases overall production cost. The process providing pimavanserin with purity of 70% will attract additional purifications, thereby leading to loss of yield and increase in cost. The procedure of trituration is not at all advisable at industrial scale. Thus, it is evident that the disclosed processes suffer a number of disadvantages to be successfully implemented on industrial scale. Thus, there remains an urgent need for the development of a process, which not only overcome one or more problems of the prior art processes as mentioned above, but also is an efficient, safe and convenient process for the preparation of pimavanserin and pharmaceutically acceptable salts thereof.
Object and Summary of the Invention
The principal object of present invention relates to novel, efficient and safe processes for the preparation of l-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-l-(l-methylpiperidin-4- yl)urea and pharmaceutically acceptable salts thereof in high yield and purity involving novel intermediates, which alleviates one or more drawbacks of prior art processes. embodiment, the present invention relates to the compound of formula IV
Figure imgf000004_0001
In another embodiment, the present invention provides a process for the preparation of compound of formula IV
Figure imgf000004_0002
comprising reacting compound of formula II or its salt with a compound of formula III.
Figure imgf000004_0003
In yet another embodiment, the present invention provides use of compound of formula IV for the preparation of pimavanserin and pharmaceutically acceptable salts thereof, comprising the reaction of formula II or its salt with the compound of formula III to give a compound of formula IV. The next step involves reaction of compound of formula IV with compound of formula V to give pimavanserin of formula IA, according to Scheme 1, which is optionally converted to its pharmaceutically acceptable salts.
Figure imgf000005_0001
Figure imgf000005_0002
IA
Scheme 1
In another embodiment, the present invention relates to the compound of formula VI
Figure imgf000005_0003
VI In yet another embodiment, the present invention provides a process for the preparation of compound of formula VI
Figure imgf000005_0004
VI
comprising reacting compound of formula V with a compound of formula III.
Figure imgf000006_0001
III
In another embodiment, the present invention provides use of compound of formula VI for the preparation of pimavanserin and pharmaceutically acceptable salts thereof, comprising the reaction of compound of formula V with compound of formula III to give a compound of formula VI. The next step involves reaction of compound of formula VI with compound of formula II or its salt to give pimavanserin of formula IA, according to Scheme 2, which is optionally converted to its pharmaceutically acceptable salts.
Figure imgf000006_0002
IA
Scheme 2
Detailed description of the Invention
The well-known intermediates of formula II and V used for the preparation of pimavanserin are reported in literature and that used in the present invention are very much prone to the formation of multiple impurities such as dimer impurity of formula VII.
Figure imgf000007_0001
The formation of impurities or the control on formation of impurities is dependent upon the reagents, solvents and conditions used for carrying out various reactions, therefore it is a challenge for the present inventors to reach at such reaction conditions, selection of solvents and reagents such that they provide pimavanserin with required purity standards, wherein the process should not involve working difficulties, involve high costs, expensive techniques/reagents, rather the process should be simple, convenient, easy to operate, environment friendly and economical.
In view of above requirements, the present invention provides processes that are simple, convenient, environment friendly and economical for industrial application. The method utilizes use of safer reagents, conditions and novel intermediates that avoids formation of multiple impurities and thereby reduces the additional requirements of purifying intermediates at various stages and accordingly reduces the use of solvents and reagents, which results in decrease in costs attributed to a more efficient use of reagents and solvents and at the same time makes process more environment friendly.
In an embodiment, the present invention relates to the compound of formula IV:
Figure imgf000007_0002
IV
In an embodiment, the present invention provides a process for the preparation of compound of formula IV:
Figure imgf000007_0003
IV
comprising reacting compound of formula II or its salt with a compound of formula III.
Figure imgf000008_0001
II III
According to present invention, the compound of formula II or its salt is reacted with compound of formula III to give compound of formula IV. Whenever a salt of compound of formula II is used it is selected from the group comprising of hydrochloride, hydrobromide, acetate and the like. The salt is neutralized to compound of formula II by use of base in a solvent, wherein the base used is selected from the group comprising organic and inorganic. The organic base used is selected from the group comprising of trimethylamine and the like. The inorganic base used is selected from alkali and alkaline earth metal carbonates, bicarbonates and the like. The alkali and alkaline earth metal is selected from the group comprising of sodium, potassium, calcium, barium and the like. The solvent used in the liberation of free base of compound of Formula II and further reaction with compound of Formula III can be same or different and is selected from the group comprising of halogenated hydrocarbons such as dichloromethane, chlorobenzene and the like, hydrocarbons such as cyclohexane, heptane, octane, toluene, xylene and the like, esters such as ethyl acetate, propyl acetate and the like, nitrile such as acetonitrile, propionitrile and the like, DMSO, DMF, water and mixtures thereof. The reaction provides compound of formula
IV.
In yet another embodiment, the present invention provides a process for the preparation of pimavanserin involving use of compound of formula IV, comprising the reaction of formula II or its salt with the compound of formula III to give a compound of formula IV. The next step involves reaction of compound of formula IV with compound of formula V to give pimavanserin of formula IA, according to Scheme 1, which is optionally converted to its pharmaceutically acceptable salts.
Figure imgf000009_0001
Figure imgf000009_0002
Figure imgf000009_0003
IA
Scheme 1
According to present invention, compound of formula II or its salt reacts with compound of formula III to give compound of formula IV. Whenever a salt of compound of formula II is used it is selected from the group comprising of hydrochloride, hydrobromide, acetate and the like. The salt is neutralized to compound of formula II by use of base in a solvent, wherein the base used is selected from the group comprising organic and inorganic. The organic base used is selected from the group comprising of trimethylamine and the like. The inorganic base used is selected from alkali and alkaline earth metal carbonates, bicarbonates and the like. The alkali and alkaline earth metal is selected from the group comprising of sodium, potassium, calcium, barium and the like. The solvent used in the liberation of free base of compound of Formula II and further reaction with compound of Formula III can be same or different and is selected from the group comprising of halogenated hydrocarbons such as dichloromethane, chlorobenzene and the like, hydrocarbons such as cyclohexane, heptane, octane, toluene, xylene and the like, esters such as ethyl acetate, propyl acetate and the like, nitrile such as acetonitrile, propionitrile and the like, DMSO, DMF, water and mixtures thereof. The compound of formula II is optionally isolated after neutralization and is further reacted with compound of formula III to obtain compound of formula IV, which is isolated or is used in-situ for further reaction. According to present invention, the compound of formula IV is treated with compound of formula V, wherein the reaction is carried out in solvent in presence of base. The solvent used is selected from the group comprising of halogenated hydrocarbons such as dichloromethane and the like, esters such as ethyl acetate, isopropyl acetate and the like, nitrile such as acetonitrile, propionitrile and the like, aromatic hydrocarbons such as toluene, chlorobenzene and the like, DMSO, DMF, water and mixtures thereof. The base used is selected from organic and inorganic, wherein organic base used is selected from the group comprising of triethylamine and the like. The inorganic base used is selected from alkali and alkaline earth metal carbonates, bicarbonates and the like. The alkali and alkaline earth metal is selected from the group comprising of sodium, potassium, calcium, barium and the like. The reaction give pimavanserin of formula IA, which is optionally converted to its pharmaceutically acceptable salts. embodiment, the present invention relates to the compound of formula VI
Figure imgf000010_0001
VI
In another embodiment, the present invention provides a process for the preparation of compound of formula VI
Figure imgf000010_0002
VI
comprising reacting compound of formula V with a compound of formula III.
Figure imgf000010_0003
V III According to present invention, the compound of formula V reacts with compound of formula III in solvent to obtain compound of formula VI. The solvent used is selected from the group comprising of halogenated hydrocarbons such as dichloromethane and the like, esters such as ethyl acetate and the like, nitrile such as acetonitrile, propionitrile and the like, water and mixtures thereof.
In another embodiment, the present invention provides use of compound of formula VI for the preparation of pimavanserin and pharmaceutically acceptable salts thereof, comprising the reaction of compound of formula V with compound of formula III to give a compound of formula VI. The next step involves reaction of compound of formula VI with compound of formula II or its salt to give pimavanserin of formula IA, according to Scheme 2, which is optionally converted to its pharmaceutically acceptable salts.
Figure imgf000011_0001
IA
Scheme 2
According to present invention, the N-(4-fluorobenzyl)-l-methylpiperidine-4-amine of formula V reacts with compound of formula III. The reaction is carried out in solvent optionally in presence of base. The solvent used is selected from the group comprising of halogenated hydrocarbons such as dichloromethane and the like, esters such as ethyl acetate and the like, nitrile such as acetonitrile and the like, water and mixtures thereof. The base used is selected from organic and inorganic, wherein organic base used is selected from the group comprising of trimethylamine and the like. The inorganic base used is selected from alkali and alkaline earth metal carbonates, bicarbonates and the like. The alkali and alkaline earth metal is selected from the group comprising of sodium, potassium, calcium, barium and the like. The reaction give compound of formula VI which is optionally isolated and is further used in next step.
According to present invention, the compound of formula VI is then treated with 4- isobutoxybenzylamine or its salt of formula II, wherein the 4-isobutoxybenzylamine salt used is selected from the group comprising of hydrochloride, hydrobromide, acetate and the like. The salt is neutralized to compound of formula II by use of base in a solvent, wherein the base used is selected from the group comprising organic and inorganic. The organic base used is selected from the group comprising of trimethylamine and the like. The inorganic base used is selected from alkali and alkaline earth metal carbonates, bicarbonates and the like. The alkali and alkaline earth metal is selected from the group comprising of sodium, potassium, calcium, barium and the like. The reaction is carried out in solvent selected from the group comprising of halogenated hydrocarbons such as dichloromethane and the like, esters such as ethyl acetate and the like, nitrile such as acetonitrile and the like, water and mixtures thereof. The reaction of compound of formula VI with compound of formula II is carried out in presence of solvent, optionally in the presence of a catalyst such as dimethylaminopyridine and the like. The solvent used is selected from the group comprising of esters such as ethyl acetate, isopropyl acetate and the like, aromatic hydrocarbons such as toluene, chlorobenzene and the like, DMSO, DMF, water and mixtures thereof. The pimavanserin of formula IA so obtained is optionally converted to pharmaceutically acceptable salts.
According to present invention, the pharmaceutically acceptable salt of pimavanserin is selected from the group comprising of hydrochloride, hydrobromide, tartrate, oxalate and the like. According to the present invention, the compound of formula IV, VI and pimavanserin or its pharmaceutically acceptable salt are isolated using one or more work-up processes such as extraction, washing, filtration and the like. The pimavanserin or its pharmaceutically acceptable salt obtained is then optionally crystallized from suitable organic solvent to get pure pimavanserin. The suitable organic solvent for crystallization is selected from the group comprising of alcohols, esters, ketones, ethers, water or mixtures thereof; particularly methanol, ethanol, n-propanol, isopropanol, n-butanol, iso-butanol, tert- butanol, methyl acetate, ethyl acetate, isopropyl acetate, tertiary butyl acetate, acetone, methyl ethyl ketone, di-isopropyl ether, tetrahydrofuran, water or mixtures thereof.
According to present invention, pimavanserin or its pharmaceutically acceptable salts obtained is having purity not less than 99.5%, preferably not less than 99.8%.
The process for the preparation of pimavanserin or salts thereof described in the present invention is demonstrated in the examples illustrated below. These examples are provided as illustration only and therefore should not be construed as limitation of the scope of the invention. It will be apparent to those skilled in the art that many modifications, both to materials and methods, may be practiced without departing from the scope of the invention. Examples
Example 1: Preparation of compound of formula IV
To a solution of (4-isobutoxyphenyl) methanamine acetate (II) (1.34 g) in dichloromethane (5 ml), added saturated solution of sodium bicarbonate at room temperature and stirred the reaction mixture for about 1 hour. The layers were separated and to the organic layer, added bis(2,5-dioxopyrrolidin-l-yl) carbonate (III) (1.57 g). The reaction mixture was stirred at room temperature for 1-2 h. On completion of reaction, the solvent was distilled off to obtain compound of formula IV as solid residue.
1H-NMR (400 MHz, DMSO, δ): 8.778 (1H, t, H), 7.16-7.18 (2H, d, CH), 6.89-6.91 (2H, d, CH), 4.17-4.19 (2H, d, CH2), 3.71-3.72 (2H, d, CH2), 2.762 (4H, s, CH2), 1.96-2.09 (1H, m, CH), 0.95-0.97 (6H, d, CH3)
Mass [M+H+]: 321.3, [M++NH3]: 338.4
Example 2: Preparation of pimavanserin using compound of formula IV
To a solution of compound of formula IV (as obtained in Example 1) in toluene (20 ml), added potassium carbonate (0.77 g) and N-(4-fluorobenzyl)-l-methylpiperidin-4-amine (V) (1.48 g) at room temperature. The temperature of reaction mixture was raised to 70-80 °C and stirred for 1-2 hours. On completion of reaction, the solvent was distilled off and ethyl acetate (30 ml) was charged to the residue. The solution was washed with water and the solvent was evaporated. The solid residue so obtained was treated with ethyl acetate/n- heptane and cooled to precipitate out pimavanserin, which was filtered and dried.
Example 3: Preparation of pimavanserin using compound of formula IV
To a solution of compound of formula IV (as obtained in Example 1) in isopropyl acetate (25 ml), added potassium carbonate (1.16 g) and N-(4-fluorobenzyl)-l- methylpiperidin-4-amine (V) (1.36 g) at room temperature. The temperature of reaction mixture was raised to 50-60 °C and stirred for about 6 hours. On completion of reaction, water (125 ml) was added to reaction mixture and stirred for another 1 hour at 50-60 °C, cooled the reaction mixture and separated layers. The solvent was distilled off from organic solvent to obtain residue. To the residue, n-heptane (25 ml) was added slowly and stirred for about 3 hours at about 40 °C. The solid pimavanserin so obtained was filtered and dried. Yield: 82%
HPLC purity: 99.4%
Example 4: Preparation of compound of formula VI
To a solution of N-(4-fluorobenzyl)-l-methylpiperidin-4-amine (V) (1.34 g) in dichloromethane (5 ml), added bis(2,5-dioxopyrrolidin-l-yl) carbonate (III) (1.57 g). The reaction mixture was stirred at room temperature for 2 h. On completion of reaction, the solvent was distilled off to obtain compound of formula VI as solid residue.
1H-NMR (400MHz, CDC13, δ): 7.39 (1H, m, CH), 7.22 (1H, m, CH), 7.00-7.06 (2H, m, CH), 4.51-4.59 (2H, d, CH2), 2.84 (6H, brs, CH2), 3.89-3.95 (1H, m, CH), 2.23 (3H, s, CH3), 1.93-1.98 (2H, m, CH2), 1.66-1.80 (4H, m, CH2)
Mass [M+H+]: 364.1
Example 5: Preparation of pimavanserin using compound of formula VI
To a solution of compound of formula VI (as obtained in Example 3) residue in toluene (75 ml), added 4-isobutoxy benzylamine (4.0 g) and catalytic amount of dimethylamino pyridine (0.05 g) at 20-25 °C. The temperature of reaction mixture was raised to 85-90 °C and stirred for 18 hours. Thereafter the solvent was distilled off to obtain desired pimavanserin.
Example 6: Preparation of pimavanserin tartrate
To solution of pimavanserin (1.5 g) in ethanol (18 ml) slowly added a solution of L- (+)-tartaric acid (0.263 g) in ethanol (12 ml) at 60-65 °C. The resulting clear mixture is slowly cooled to room temperature. The solid so obtained is filtered and dried to obtain pimavanserin tartrate.


Claims

Claims:
1. A com ound of formula IV
Figure imgf000016_0001
IV
2. A rocess for the preparation of compound of formula IV
Figure imgf000016_0002
comprising reacting compound of formula II or its salt with a compound of formula III.
Figure imgf000016_0003
II III
The process according to claim 2, wherein salt of compound of formula II is selected from the group comprising of hydrochloride, hydrobromide and acetate.
The process according to claim 2, wherein the reaction is carried out in solvent selected from the group comprising of halogenated hydrocarbons, hydrocarbons, esters, nitrile, DMSO, DMF, water and mixtures thereof.
Use of compound of formula IV for the preparation of pimavanserin and its pharmaceutically acceptable salts.
A process for the preparation of pimavanserin comprising:
(i) reacting compound of formula II or its salt with the compound of formula III to give a compound of formula IV;
Figure imgf000017_0001
II III
Figure imgf000017_0002
IV
(ii) reacting compound of formula IV with compound of formula V to give pimavanserin of formula IA; and
Figure imgf000017_0003
IA
(iii) optionally, converting compound of formula IA to its pharmaceutically acceptable salts.
7. The process according to claim 6, wherein the reaction of step (i) is carried out in solvent selected from the group comprising of hydrocarbons, halogenated hydrocarbons, esters, nitriles, DMSO, DMF, water and mixtures thereof.
8. The process according to claim 6, wherein the reaction of step (ii) is carried out in solvent and in presence of base.
9. The process according to claim 8, wherein solvent is selected from the group comprising of hydrocarbons, halogenated hydrocarbons, esters, nitriles, DMSO, DMF, water and mixtures thereof.
10. The process according to claim 8, wherein base used is selected from the group comprising of organic and inorganic.
11. The process according to claim 10, wherein organic base used is trimethylamine.
12. The process according to claim 10, wherein the inorganic base used is selected from alkali and alkaline earth metal carbonates and bicarbonates.
PCT/IN2018/050053 2017-07-03 2018-02-02 Process for the preparation of 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1- methylpiperidin-4-yl)urea and salts thereof WO2019008595A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201711023281 2017-07-03
IN201711023281 2017-07-03

Publications (1)

Publication Number Publication Date
WO2019008595A1 true WO2019008595A1 (en) 2019-01-10

Family

ID=64950742

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2018/050053 WO2019008595A1 (en) 2017-07-03 2018-02-02 Process for the preparation of 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1- methylpiperidin-4-yl)urea and salts thereof

Country Status (1)

Country Link
WO (1) WO2019008595A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111303013A (en) * 2020-04-08 2020-06-19 福建省微生物研究所 A kind of preparation method of pemaserin

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013142307A1 (en) * 2012-03-19 2013-09-26 Abide Therapeutics Carbamate compounds and of making and using same
CA2992728A1 (en) * 2015-07-20 2017-01-26 Acadia Pharmaceuticals Inc. Methods for preparing n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form c
WO2017054786A1 (en) * 2015-10-02 2017-04-06 Zentiva, K. S. A production method of 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin- 4-yl)urea and its deuterated analogs

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013142307A1 (en) * 2012-03-19 2013-09-26 Abide Therapeutics Carbamate compounds and of making and using same
CA2992728A1 (en) * 2015-07-20 2017-01-26 Acadia Pharmaceuticals Inc. Methods for preparing n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form c
WO2017054786A1 (en) * 2015-10-02 2017-04-06 Zentiva, K. S. A production method of 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin- 4-yl)urea and its deuterated analogs

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111303013A (en) * 2020-04-08 2020-06-19 福建省微生物研究所 A kind of preparation method of pemaserin
CN111303013B (en) * 2020-04-08 2023-10-13 福建省微生物研究所 A kind of preparation method of pimaserin

Similar Documents

Publication Publication Date Title
US10626091B2 (en) Process for the preparation of enzalutamide
US10358423B2 (en) Processes for the preparation of 4-alkoxy-3-(acyl or alkyl)oxypicolinamdes
US9771317B2 (en) Process for preparing lacosamide and related compounds
US20120108809A1 (en) Process for preparation of efavirenz
US7541471B2 (en) Synthesis of himbacine analogs
WO2019008595A1 (en) Process for the preparation of 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1- methylpiperidin-4-yl)urea and salts thereof
US12173013B2 (en) Synthetic processes and synthetic intermediates
US9802896B2 (en) Process for large scale production of N-[4-(1-cyclobutyl piperidin-4-yloxy) phenyl]-2-(morpholin-4-yl) acetamide dihydrochloride
EP3242879B1 (en) Novel process for the preparation of dipeptidyl peptidase-4 (dpp-4) enzyme inhibitor
EP3092222B1 (en) Improved fingolimod process
KR20210092768A (en) Synthetic Method for Preparation of 1-((3S,4R)-4-(2,6-difluoro-4-methoxyphenyl)-2-oxopyrrolidin-3-yl)-3-phenylurea
JP5396841B2 (en) Process for producing α-trifluoromethyl-β-substituted-β-amino acids
KR101085170B1 (en) (S) -Rivastigmine Production Method
CN101654426A (en) Method for preparing ilomastat
KR20050062944A (en) New process for preparing diisopropyl ((1-((2-amino-6-chloro-9h-purin-9-yl)methyl)cyclopropyl)oxy)-methylphosphonate
US20240124393A1 (en) Process and intermediates for preparation of omaveloxolone and salts thereof
JPH045026B2 (en)
US20220371995A1 (en) Synthesis method for halofuginone and halofuginone intermediates
KR20250014306A (en) Method for Producing Allulose Dimer
EP2152697A2 (en) Process for the preparation of alfuzosin and salts thereof
JPWO2005026108A1 (en) Process for producing N, N'-dialkoxy-N, N'-dialkyloxamide
JPH07109280A (en) Production of hydantocidin
JPH0316339B2 (en)
WO2015150887A1 (en) Process for the preparation of anagliptin or its salts
JP2002322128A (en) Method for producing benzyl derivative

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18827787

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18827787

Country of ref document: EP

Kind code of ref document: A1

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载